Groundhog Day for Amarin (AMRN); MKM Not Positive on NCE Status Although Company Remains Upbeat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/8/2026
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Brent climbs $1 on uncertainty over end to Iran war
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
- S&P closes at record high as soft jobs report eases rate-hike concerns
- Atlassian results seen as 'game changer' for AI kills software worries
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Vistra Energy (VST) Reports Q2 results
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Volatility to Continue for Amarin (AMRN) with No NCE Decision, But Serious Upside Exists - Jefferies
November 19, 2012 8:20 AM ESTJefferies commented on Amarin Corporation (NASDAQ: AMRN) after this month's FDA Orange Book update contained no decision on 5-year versus 3-year exclusivity for Vascepa.
While the firm expects more volatility with no NCE decision, Amarin's 10-Q, stating - "We have been informed by FDA that the FDA has drafted a proposed response letter to our exclusivity request, that such draft response letter has been circulated internally at the FDA for comment and the FDA has been considering the issue actively" - is a modest positive.
"There may be... More
Amarin Corp (NASDAQ: AMRN) NCE status isn't update in FDA Orange Book for October
November 16, 2012 2:18 PM ESTAmarin Corp (NASDAQ: AMRN) NCE status isn't update in FDA Orange Book for October.... More
Amarin (AMRN) Sees Downside Action
November 16, 2012 1:22 PM ESTAmarin Corporation plc (NASDAQ: AMRN) sees downside. NCE decision expected soon.... More
Amarin (AMRN) Higher as Teva (TEVA) Said to be Waiting in the Wings for a Takeover
November 15, 2012 7:40 AM ESTAmarin Corp Plc (NASDAQ: AMRN) is surging higher in pre-open trading Thursday following reports from Calcalist that Teva Pharmaceutical (NASDAQ: TEVA) is the leading candidate to acquire the company. AstraZeneca (NYSE:... More
